Locksley Resources (ASX: LKY) hits 99.5% purity antimony trioxide milestone, opening U.S. defense supply chain pathway
How Accenture is using Google Cloud and Wiz to close security blind spots in modern multi-cloud infrastructure
Read More 6 minute read Pharma Industry News Why Vir Biotechnology’s tobevibart and elebsiran combo may signal a breakthrough in hepatitis delta treatment Vir Biotechnology’s hepatitis delta therapy shows 66% RNA clearance at 48 weeks. Find out why this could redefine treatment ahead of 2027 trial results. byVenkateshNovember 10, 2025